Literature DB >> 16239399

The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines.

Raymond R Mattingly1, Janice M Kraniak, Joshua T Dilworth, Patricia Mathieu, Beverly Bealmear, James E Nowak, Joyce A Benjamins, Michael A Tainsky, John J Reiners.   

Abstract

Type 1 neurofibromatosis (NF1) is a common autosomal dominant disorder that results in neuroectodermal tumors. The NF1 tumor-suppressor gene encodes neurofibromin, which includes a GTPase-activating domain for Ras inactivation. Affinity purification showed N-Ras to be the predominant activated isoform of Ras in two independent neurofibrosarcoma cell lines from NF1 patients (lines ST88-14 and NF90-8). These NF1 cells also demonstrated increased constitutive activity of the extracellular signal-regulated kinases 1 and 2 (ERK1,2) mitogen-activated protein (MAP) kinases compared with a sporadic malignant schwannoma cell line that maintains neurofibromin expression (STS-26T). Thus, MAP kinase kinase (MEK) inhibitors may be a rational approach to NF1 therapy. The MEK inhibitors PD98059 [2'-amino-3'-methoxyflavone], PD184352 (also called CI-1040) [2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide], and U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene] all produced concentration-dependent suppression of the proliferation of the three cell lines. Individual MEK inhibitors had similar effects in all three cell lines. However, only the antiproliferative effects of PD184352 correlated closely with the elimination of ERK1,2 MAP kinase activities. PD98059 was primarily cytostatic, whereas U0126 and PD184352 were cytotoxic. Only PD184352 induced apoptosis in all three lines, as indicated by morphology, activation of DEVDase, procaspase-3 cleavage, and the appearance of populations having sub-G(0)/G(1) DNA contents. The differential effects of the MEK inhibitors on cell survival were not dependent on p53 status or effects on the ERK5 pathway. PD184352 was also proapoptotic to primary rat Schwann cells. Hence, although PD184352 effectively killed neurofibrosarcoma cells, its effects on normal Schwann cells may limit its usefulness in the clinic.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16239399     DOI: 10.1124/jpet.105.091454

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  28 in total

Review 1.  How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.

Authors:  Ethan J Brock; Kyungmin Ji; John J Reiners; Raymond R Mattingly
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

2.  Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.

Authors:  Joshua T Dilworth; Jonathan W Wojtkowiak; Patricia Mathieu; Michael A Tainsky; John J Reiners; Raymond R Mattingly; Chad N Hancock
Journal:  Cancer Biol Ther       Date:  2008-12-07       Impact factor: 4.742

Review 3.  Ras and Rap1: A tale of two GTPases.

Authors:  Seema Shah; Ethan J Brock; Kyungmin Ji; Raymond R Mattingly
Journal:  Semin Cancer Biol       Date:  2018-04-03       Impact factor: 15.707

4.  A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells.

Authors:  Komal M Sane; Michelle Mynderse; Daniel T Lalonde; Ivory S Dean; Jonathan W Wojtkowiak; Farid Fouad; Richard F Borch; John J Reiners; Richard A Gibbs; Raymond R Mattingly
Journal:  J Pharmacol Exp Ther       Date:  2010-01-19       Impact factor: 4.030

5.  Aborted autophagy and nonapoptotic death induced by farnesyl transferase inhibitor and lovastatin.

Authors:  Jonathan W Wojtkowiak; Komal M Sane; Miriam Kleinman; Bonnie F Sloane; John J Reiners; Raymond R Mattingly
Journal:  J Pharmacol Exp Ther       Date:  2011-01-12       Impact factor: 4.030

6.  Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner.

Authors:  Thomas J Turbyville; Demirkan B Gürsel; Robert G Tuskan; Jessica C Walrath; Claudia A Lipschultz; Stephen J Lockett; David F Wiemer; John A Beutler; Karlyne M Reilly
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

7.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Authors:  Walter J Jessen; Shyra J Miller; Edwin Jousma; Jianqiang Wu; Tilat A Rizvi; Meghan E Brundage; David Eaves; Brigitte Widemann; Mi-Ok Kim; Eva Dombi; Jessica Sabo; Atira Hardiman Dudley; Michiko Niwa-Kawakita; Grier P Page; Marco Giovannini; Bruce J Aronow; Timothy P Cripe; Nancy Ratner
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

8.  Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors.

Authors:  Quanwen Li; Albert B Chow; Raymond R Mattingly
Journal:  J Pharmacol Exp Ther       Date:  2009-12-01       Impact factor: 4.030

9.  A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks.

Authors:  Dai Mohri; Hideaki Ijichi; Koji Miyabayashi; Ryota Takahashi; Yotaro Kudo; Takashi Sasaki; Yoshinari Asaoka; Yasuo Tanaka; Tsuneo Ikenoue; Keisuke Tateishi; Minoru Tada; Hiroyuki Isayama; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2015-11-27       Impact factor: 7.527

10.  Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Ras-transformed breast epithelial cells.

Authors:  Quanwen Li; Raymond R Mattingly
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.